Baseline demographics and disease characteristics
| Characteristic, mean±SD* | Adalimumab N=165 |
| Age, years | 40.6±11.9 |
| Women, n (%) | 90 (55) |
| BMI (kg/m2) | 26.6±5.8 |
| Smoker, yes, n (%) | 39 (24) |
| Symptom duration, years | 7.24±7.1 |
| HLA-B27-positive, n (%)† | 103 (63) |
| Prior DMARD use, n (%) | 115 (70) |
| Concomitant DMARD use, n (%) | 79 (48) |
| Elevated hs-CRP, n (%) | 72 (44) |
| Swollen joint count (0–76) | 6.7±6.9 |
| Tender joint count (0–78) | 13.3±14.5 |
| Physician Global Assessment of disease activity (0–100) | 58.7±15.3 |
| Patient Global Assessment of pain (0–100) | 64.9±14.9 |
| Patient Global Assessment of disease activity (0–100) | 65.8±15.5 |
| Enthesitis count (0–29) | 7.0±6.8 |
| Dactylitis count (0–20) | 0.5±1.1 |
| BASDAI (0–10) | 5.62±1.7 |
| ASDAS | 2.99±0.8 |
*Unless otherwise noted.
↵†n=164.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; DMARD, disease-modifying antirheumatic drug; HLA, human leucocyte antigen; hs-CRP, high-sensitivity C-reactive protein.